SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: November 19, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                     Delaware                         52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


Registrant's telephone number, including area code (301) 417-0770


No Exhibits are being filed with this report.


CytoGam, RespiGam and Synagis are registered trademarks of the Company.

<PAGE>





MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated November 19, 1999:

FOR IMMEDIATE RELEASE

                   MEDIMMUNE TO EXCHANGE 0.15 SHARES FOR EACH
                  U.S. BIOSCIENCE SHARE IN PROPOSED ACQUISITION

Gaithersburg,  MD, and West  Conshohocken,  PA, November 19, 1999 --- MedImmune,
Inc. (Nasdaq:  MEDI) and U.S. Bioscience,  Inc. (Amex: UBS) announced today that
each share of U.S.  Bioscience common stock will be exchanged for 0.15 shares of
MedImmune  common stock in the previously  announced  proposed merger of the two
companies. Any fractional shares of U.S. Bioscience stock will be paid in cash.

The exchange  ratio was based on  MedImmune's  average  closing price of $106.36
over a 20-day  trading  period that ended on November  18th,  three trading days
prior to the U.S.  Bioscience  Special  Meeting of  Stockholders,  being held to
consider the acquisition. The Special Meeting is scheduled for 10:00 a.m. EST on
November 23, 1999.  Completion of the merger, if approved,  is expected to occur
shortly after the Special Meeting.

The offering of MedImmune  common  stock in  connection  with the merger is made
under an effective S-4 Registration  Statement.  The offering is being made only
by means of a proxy statement/prospectus  relating to the merger, which has been
distributed to U.S. Bioscience stockholders.

MedImmune,  Inc., located in Gaithersburg,  Maryland, is a biotechnology company
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.

U.S.  Bioscience,  Inc.,  based  in  West  Conshohocken,   Pennsylvania,   is  a
pharmaceutical  company specializing in the development and commercialization of
products for patients with cancer and AIDS.

Statements about the proposed merger are forward-looking statements that involve
risks and  uncertainties.  Among the factors that could cause actual  results of
MedImmune,  U.S.  Bioscience or the combined  company to differ  materially from
those in the forward  looking  statements  are:  the failure of the merger to be
consummated, the ability of the companies to successfully integrate,  challenges
inherent  in new  product  development  and  marketing,  governmental  laws  and
regulations, including possible healthcare reform, the availability of favorable
tax and accounting  treatment for the merger and those factors in the companies'
reports  and filings  with the U.S.  Securities  and  Exchange  Commission.  The
companies  disclaim  any  intention  or  obligation  to  update  or  revise  any
forward-looking statements.

<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)



November 19, 1999        /s/David M. Mott
-----------------        ----------------
Signed by:               David M. Mott, Vice Chairman and
                         Chief Financial Officer
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE TO EXCHANGE 0.15 SHARES", "secsgml_size_bytes": 4423}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99761196"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        Date of Report: November 19, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                     Delaware                         52-1555759
             (State of Incorporation)              (I.R.S. Employer
                                                   Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

Registrant's telephone number, including area code (301) 417-0770

No Exhibits are being filed with this report.

CytoGam, RespiGam and Synagis are registered trademarks of the Company.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated November 19, 1999:

FOR IMMEDIATE RELEASE

                   MEDIMMUNE TO EXCHANGE 0.15 SHARES FOR EACH
                  U.S. BIOSCIENCE SHARE IN PROPOSED ACQUISITION

Gaithersburg,  MD, and West  Conshohocken,  PA, November 19, 1999 --- MedImmune,
Inc. (Nasdaq:  MEDI) and U.S. Bioscience,  Inc. (Amex: UBS) announced today that
each share of U.S.  Bioscience common stock will be exchanged for 0.15 shares of
MedImmune  common stock in the previously  announced  proposed merger of the two
companies. Any fractional shares of U.S. Bioscience stock will be paid in cash.

The exchange  ratio was based on  MedImmune's  average  closing price of $106.36
over a 20-day  trading  period that ended on November  18th,  three trading days
prior to the U.S.  Bioscience  Special  Meeting of  Stockholders,  being held to
consider the acquisition. The Special Meeting is scheduled for 10:00 a.m. EST on
November 23, 1999.  Completion of the merger, if approved,  is expected to occur
shortly after the Special Meeting.

The offering of MedImmune  common  stock in  connection  with the merger is made
under an effective S-4 Registration  Statement.  The offering is being made only
by means of a proxy statement/prospectus  relating to the merger, which has been
distributed to U.S. Bioscience stockholders.

MedImmune,  Inc., located in Gaithersburg,  Maryland, is a biotechnology company
focused on developing and marketing products that address medical needs in areas
such as infectious disease,  transplantation medicine,  autoimmune disorders and
cancer.

U.S.  Bioscience,  Inc.,  based  in  West  Conshohocken,   Pennsylvania,   is  a
pharmaceutical  company specializing in the development and commercialization of
products for patients with cancer and AIDS.

Statements about the proposed merger are forward-looking statements that involve
risks and  uncertainties.  Among the factors that could cause actual  results of
MedImmune,  U.S.  Bioscience or the combined  company to differ  materially from
those in the forward  looking  statements  are:  the failure of the merger to be
consummated, the ability of the companies to successfully integrate,  challenges
inherent  in new  product  development  and  marketing,  governmental  laws  and
regulations, including possible healthcare reform, the availability of favorable
tax and accounting  treatment for the merger and those factors in the companies'
reports  and filings  with the U.S.  Securities  and  Exchange  Commission.  The
companies  disclaim  any  intention  or  obligation  to  update  or  revise  any
forward-looking statements.
SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                         MEDIMMUNE, INC.
                         ----------------
                         (Registrant)

November 19, 1999        /s/David M. Mott
-----------------        ----------------
Signed by:               David M. Mott, Vice Chairman and
                         Chief Financial Officer